JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal
9. April 2026JW Pharmaceutical has entered into a licensing agreement with China-based Gan & Lee Pharmaceuticals to obtain exclusive rights in Korea for bofanglutide, an advanced GLP-1 receptor agonist. Under the terms of the deal, JW Pharmaceutical will oversee clinical development, regulatory submissions, and commercialization within the Korean market, while Gan & Lee will supply the necessary data and documentation to support investigational new drug applications and product approvals. The total agreement value may reach $81.1 million, including an upfront payment of $5 million and additional milestone-based payments linked to approvals across multiple indications. Medical products usually require MFDS certification in order to be approved for import and sale in Korea.
The drug has demonstrated promising outcomes in clinical studies, including a Phase 2b trial where patients achieved an average weight reduction of 17.3 percent over 30 weeks with biweekly administration. JW Pharmaceutical plans to initiate Phase 3 trials in Korea later this year, targeting obesity and type 2 diabetes. The partnership aligns with growing global and regional demand for GLP-1 therapies, with the Asia-Pacific market projected to expand significantly in the coming years. Both companies emphasized that the collaboration will support the advancement of innovative treatments and broaden access to new therapeutic options in Korea.
Feel free to contact us any time if you need assistance or have any questions regarding Korean certifications like KC, KC EMC, KCs, KCs for explosion safety products, MFDS certification for medical products or KGS factory registration.
Tel. Europe: +49-69-271 37 69 259
Tel. US: +1 773 654-2673
Email: info@korea-certification.com
For more information you can download our free brochure “Korea Certification Made Easy – The Booklet“.
